THE MALABSORPTION BLOOD TEST TRIAL WILL HELP DETERMINE THE BENEFITS OF PANCREATIC ENZYME REPLACEMENT THERAPY IN PATIENTS WITH MILD TO MODERATE EXOCRINE PANCREATIC INSUFFICIENCY.

Recruiting

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(2 sites)

United States

Johns Hopkins Medicine, Baltimore, Maryland

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania